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September 2010 was the 70th anniver-
sary of the Battle of Britain. A number of
commentators, historians, and other pun-
dits have debated the significance of the
battle: was it a truly significant turning
point (or tipping point in present parlance)
in World War II? Similarly, historians of
science and others will no doubt be
mulling over the true significance of the
human genome sequencing project 70
years hence and thereafter. In Drawing the
Map of Life, veteran science journalist and
author Victor McElheny offers a view
‘‘inside the human genome project’’ that
covers the origin of the project in the
United States, its development and imple-
mentation, and its impact since its ‘‘com-
pletion’’ in 2000. It is a hugely readable
account that gives the reader a sense of the
excitement and drama that gripped the
main protagonists along with a description
of the technological advances that made
the project feasible and affordable. It relies
heavily on interviews with a number of
scientists, mainly from the US, newspaper
articles, and radio and television reports,
but pays scant attention to the interna-
tional character of the project. It is
important to reaffirm that one country
did not do it alone; it was an international
effort and the many partners are justifiably
proud of their contribution.
There seems little controversy that it
was Robert Sinsheimer, then chancellor of
the University of California at Santa Cruz,
who was the first to call a meeting (in May
1985) to discuss the feasibility of sequenc-
ing the human genome. As related by
McElheny, among the dozen or so scien-
tists at the meeting was John Sulston from
the Laboratory of Molecular Biology
(LMB) in Cambridge, United Kingdom,
who published his own account of the
project in 2002, a year before the
completion of the sequence was declared
[1]. John, with Bob Waterston of Wash-
ington University, St. Louis, were arguably
the first to invest heavily in the sequencing
of an animal genome, Caenorhabditis elegans,
funded jointly by the Medical Research
Council (MRC) in the UK and the
National Institutes of Health in the US.
This was a unique partnership champi-
oned by the Secretary of the MRC, Sir
Dai Rees, and Jim Watson, Director of the
National Center for Human Genome
Research at the National Institutes of
Health, respectively. When John and
Bob were being solicited by Frederick
Bourke to join his private effort to
sequence the human genome, it was not
surprising that Watson alerted the MRC
to the danger of losing their star sequencer
and an approach was made to the Well-
come Trust in the UK to help fund a
human genome sequencing programme.
The Trust responded in 1992 by not
only agreeing to join the MRC in
supporting an initiative that would play a
role in mapping, sequencing, and decod-
ing the human genome and the genomes
of other organisms, but also, for the first
time in its history, to establish its own
research station, now called the Wellcome
Trust Sanger Institute at Hinxton, Cam-
bridgeshire. This decision was not due to a
change of strategy by the Wellcome Trust,
but was a pragmatic response to the need
to get a large sequencing facility up and
running as soon as possible. John Sulston
and I visited a number of possible sites,
including a poultry research centre where
John thought the chicken sheds would
provide adequate housing for sequencing!
A number of universities were considered,
but it became clear that none were likely
to be able to provide suitable accommo-
dation in a timely fashion. John identified
a site at Hinxton, Cambridgeshire, for-
merly a Tube Investments plc engineering
research station, purchased by Capital and
Counties plc, who had ambitious plans for
a business park—a venture that never got
off the ground. (At the time, there were ill-
founded rumours that Tube Investments
had been involved in the UK’s nuclear
weapons research.) The Trust acquired
the site in the autumn of 1992 and the
metallurgy laboratories were re-fitted as a
state-of-the-art sequencing facility in a
period of a few months. The first new
occupants moved in during March 1993,
and by the end of the year there were over
80 staff on site and space was tight. In
October 1993, the facility was formally
opened and named by Fred Sanger as the
Sanger Centre.
In a chapter called ‘‘Building the
Toolbox’’, McElheny describes the recom-
binant DNA technologies developed by
Hamilton O. Smith, Fred Sanger, Walter
Gilbert, Kary Mullis, and Lee Hood,
amongst others, that enabled the manip-
ulation of DNA, its amplification and
sequencing, and the development of auto-
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describe some of the early efforts to garner
public support (and funding) of the project,
particularly in the US, and the role of Jim
Watson in convincing Congress to fire the
starting pistol.
John, Bob, and many of their colleagues
were determined that the effort should be
international in scope and involve all
laboratories able to engage in large-scale
sequencing; they were also concerned at
the apparent lack of cooperation in the
human genetics community (in contrast to
their experience with the worm commu-
nity). To promote international coordina-
tion and cooperation, the Wellcome Trust
decided to host a meeting to which all
relevant parties would be invited. It was
decided to hold the meeting on ‘‘neutral
ground’’ in Bermuda, and in February
1996, the first meeting of representatives
from sequencing centres and funding
agencies around the world met and
established a coordinated effort, in the
public domain, to sequence the human
genome. Some 50 or so scientists and
administrators from the US, UK, France,
Germany, and Japan (joined a year or so
later by China) discussed the scientific
strategy for a distributed sequencing effort
and, in particular, agreed on a policy for
the release of data generated by the
project, the so-called Bermuda Principles
[2]. The principles evinced the benefits of
the immediate release of raw data on the
Internet without any privileged ‘‘first sight
or use’’ and to pledge not to seek patent
protection. These principles did not re-
ceive universal acclaim, and caused con-
sternation among a few groups who were
concerned that their institutions, funding
bodies, or governments might be unwilling
to agree to the data release guidelines.
However, it was made clear that continued
membership in the human genome se-
quence ‘‘club’’ required agreement to the
principles. In the end, these misgivings
proved unfounded. These data release
principles helped assuage the impression
that a small cabal of privileged and
massively funded researchers would be
given an unprecedented advantage over
the rest of the scientific community. The
principles have been extended to many
other large-scale collaborative projects in
biology, such as the SNPs Consortium
(TSC) and the Structural Genomics Con-
sortium, and have driven scientific prog-
ress and industrial application alike.
McElheny covers the ‘‘race’’ between
the public consortium (managed by Fran-
cis Collins of the National Human Ge-
nome Research Institute, Ari Patrinos of
the Department of Energy, and myself of
the Wellcome Trust) and the private
company, Celera, headed by Craig Ven-
ter. It is well documented how Craig broke
ranks and decided to commercialise the
sequence and seek patent protection on a
number of genes. As a result, the ‘‘race’’ to
sequence the human genome began. It is
perhaps salutary to report that eventually
Celera deposited its sequence in GenBank
and the human sequence and that of many
other organisms are freely available to
anyone with access to the Internet.
McElheny’s account admirably covers
the period from the early days of recom-
binant DNA (1960s) through to 2010 and
the days of the exploitation of the
knowledge garnered from the project.
There is significant debate in the media,
no doubt reflecting that 2010 is the 10th
anniversary of the release of the ‘‘working
draft’’ of the genome about the worth of
the project. One camp, notably espoused
by Craig Venter in a recent article in Der
Spiegel [3], casts doubts on the (medical)
worth of the project. McElheny seems to
be on the other side, admitting that many
benefits lie in the future, but that some, for
example diagnostic tools in treatment of
some cancers and in the emerging field of
pharmacogenomics, are already part of
good medical practise in America. It is
comprehensive, but, inevitably, superficial
in its treatment of many of the social and
political aspects of the project. For exam-
ple, the early role of the Human Genome
Organisation (HUGO), the grassroots
organisation established by the early
pioneers in genomics, does not even get
a mention. The inevitable stresses and
strains that beset the public programme
and the behind the scenes negotiations
that led to the ‘‘Clinton-Blair’’ joint
statement in 2000, in which they applaud-
ed the decision to rapidly release human
DNA data into the public domain, are yet
to be related. This is not, therefore, a
definitive history of the human genome
project, or even a definitive history of the
American contribution to the project. It is,
however, a very entertaining and well-
written account of the material it covers
and provides, unusually for a ‘‘popular’’
treatise, a comprehensive series of notes to
sources (some 24% of the book!) that will
lead the keen student into deeper studies.
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